Articles Posted in Xarelto

Xarelto is a relatively new type of blood-thinning medication in a class of drugs called New Oral Anticoagulants (NOACs).

Xarelto is manufactured by Bayer AG and sold in the United States with Bayer’s marketing partner, Janssen Pharmaceuticals. Janssen is a subsidiary of Johnson & Johnson.

These companies market Xarelto for patients at high risk of developing serious clotting disorders such as stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). A PE is deadly health condition in which a clot forms and then dislodges itself and travels through the circulatory system until it reaches the lungs. One in a lung, it can tear a hole in the tissues, causing serious illness or death.

Patients at risk for these conditions normally require a blood thinner such as Warfarin. While Warfarin is generally effective, patients must closely watch their diet and have regular blood tests to control their dosage. If the dosage is off, patients can develop life-threatening side effects. Xarelto, on the other hand, is supposed be as effective without requiring constant dose monitoring.
Continue reading

Philadelphia flyers Defenseman, Kimmo Timonen hopes to recover from a serious clotting disorder to a point, which will allow him to get back on the ice. According to a recent news article from Courier-Post, Timonen has been unable to play this season after being diagnosed with blood clots in his lungs and legs.

As part of his treatment for his serious clotting disorder, Timonen has been taking Xarelto. Xarelto is a member of a class of drugs known as New Oral Anticoagulants (NOACs). NOACs are a newer alternative to traditional blood thinners such as Warfarin. Those with clotting disease are at a high risk for stroke if one of the clots breaks free from a vein and block an artery providing blood to patient’s brain. Clots can also travel to patient’s lungs and tear a hole known as a pulmonary embolism (PE). Both of these can result in serious personal injury or death.

One advantage touted by makers of Xarelto is patients are not required to have frequent blood tests, and closely monitor their diets to keep their dosage in check. If Warfarin is administered in an incorrect dosage, it can cause life-threatening side effects. Doctors will use results of frequent blood tests to adjust a patient’s dosage from time to time.
Continue reading

It is hard to watch TV these days without seeing ads for Xarelto. Xarelto is a member of a class of drugs known as New Oral Anticoagulants (NOACs). Other members of this class include Eliquis and Pradaxa. Xarelto is the brand name in the United States for rivaroxaban manufactured by Bayer AG. Janssen, a subsidiary of Johnson & Johnson, markets Xarelto.

The company claims Xarelto can help patients suffering from a condition known as atrial fibrillation (Afib). Afib patients are a higher risk for serious diseases such as stroke and will typically be treated with a blood thinner to prevent serious clots from forming. Blood clots can cause strokes and other dangerous conditions such as a pulmonary embolism (PE).

Until the development of NAOCs, doctors would prescribe medications such as Warfarin to Afib patients. While effective, Warfarin patients need to have regular blood tests to make sure they are getting the correct dosage. If the dosage is no longer correct, a patient’s doctor can adjust the dose. If a patient fails to have his or her blood checked and is taking an improper dose, they can suffer serious side effects.
Continue reading

New drugs can yield billions of dollars for pharmaceutical companies. Because it takes many years to develop a drug, undergo clinical trials, and get it to market, drug companies will do virtually anything to get as much profit as possible for each new drug. This is especially true when considering that many proposed drugs will never make it through development, past clinical trials, or ever receive FDA approval. Some drugs are later found to be toxic or otherwise harmful to patients after being put on the market and then have to be withdrawn, while the manufacturer may be subjected to numerous lawsuits.
Continue reading

Xarelto is a member of a class of drugs known as New Oral Anticoagulants (NOACs), along with Eliquis, and Pradaxa. These drugs were designed to replace older blood-thinning drugs such as warfarin, which requires frequent monitoring of a patient’s blood to prevent dangerous side effects. The problem with Xarelto and these other NOACs is they have been shown to cause serious bleeding disorders, including internal bleeding, intracranial bleeding, and hemorrhaging.

If patient experiences a bleeding disorder after taking Xarelto, there is no approved cure for the disease, and the condition can be fatal. In other words, when a patient comes into the emergency with serious internal bleeding caused by Xarelto, there is not much doctors can do besides transfuse blood and try to make the patient comfortable.

According to a recent news article from the Madison Record, the makers of Xarelto now are being sued over the drug’s inability to clot in a timely manner. Bayer AG is the manufacturer of Xarelto and Janssen Pharmacutica (a subsidiary of Johnson & Johnson) is the marketing partner in the United States.
Continue reading

Xarelto is a member of class of drugs known as New Oral Anticoagulants (NOACs) and has been the subject of many recent dangerous drug lawsuits. The makers of Xarelto (Bayer AG and Johnson & Johnson) produced a drug linked to serious clotting disorders, internal bleeding, and intracranial bleeding. Patients were not sufficiently warned of these dangerous side effects and were not given a chance to make an informed decision before taking the drug.

According to a recent news article from Bloomberg, Xarelto manufacturers are fighting a push to consolidate the many lawsuits that have been filed. Plaintiffs have requested all cases be consolidated and heard in the U.S. District Court in Illinois by Judge David Herndon. Plaintiffs have specifically alleged 65 Xarelto deaths have already occurred.
Continue reading

Xarelto is a member of a new class of anticoagulant drugs that has been approved to reduce the risk of stroke and other blood-clotting disorders in patients with atrial fibrillation.

The new drug, manufactured by Janssen, has been linked to cases of serious internal bleeding disorders, including hemorrhaging and intracranial bleeding. If a patient takes Xarelto and begins to bleed internally, there is no approved treatment or way to reverse the serious and potentially fatal side effect of the drug.
Continue reading

As our Xarelto attorneys have discussed on other blog entries, Johnson and Johnson, Bayer, U.S., and German drugmakers involved with the production and marketing of the drug are performing new studies to increase the profit potential for their flagship anticoagulant.

According to a recent article from The Wall Street Journal, the drugmakers have developed two studies to show that Xarelto is effective in treating patients with Acute Coronary Syndrome (ACS). This is significant because the U.S. Food and Drug Administration (FDA) has rejected previous efforts to seek approval to market Xarelto to ACS patients.

The reason for the rejections was that the FDA was concerned flawed study data did not establish that the benefit of Xarelto for ACS patients outweighed the known risk of serious and potentially fatal side effects.

The drug companies have also included two other blood disorders in the study, including strokes caused by clots of unknown origins and peripheral artery disease.The danger related to Xerelto is that it has been shown to cause an increased risk of internal bleeding, including intracranial bleeding.

In any dangerous drugs lawsuit, there can be a variety of claims presented under a theory of negligence. As with any negligence action, the plaintiff must prove by a preponderance of the evidence that the defendant owed a duty of care to protect foreseeable persons from foreseeable harm. There is generally no question that a drug company owes a duty of care to protect users of their pharmaceuticals from foreseeable injury.
Continue reading

A recent article in The New York Times examines the risks of Pradaxa. Pradaxa, like Xarelto, is among a relatively new class of blood-thinning drugs turning huge profits for the manufacturer.

Patients who had been taking Warfarin, the traditionally prescribed medication to aid in the prevention of strokes, needed to get their blood levels checked every few weeks. Depending on results,, the dose of Warfarin would be adjusted.

Pradaxa has been marketed in a way that users are led to believe regular blood testing is not necessary with this new drug. They were told there is no need to adjust the dose, like you do with Warfarin. However, as your Boston medical malpractice lawyers can explain, this advice by the marketing arm of the pharmaceutical company can lead to internal bleeding and bruising, including intracranial hemorrhaging.

As noted in the article, the more convenient nature of Pradaxa was a key reason the U.S. Food and Drug Administration (FDA) fast-tracked its approval and allowed it to hit the market after only a single large clinical trial.
Continue reading